SG Americas Securities LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 548.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,409 shares of the company's stock after purchasing an additional 28,259 shares during the quarter. SG Americas

Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,316 shares of the company's stock after selling 282,981 shares during the period.

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA).

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70.

DAVENPORT and Co LLC increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 248.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 217,897 shares of the company's stock after purchasing an additional 155,334 shares during the quarter.

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition,.

Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglycerides and 85% reduction in acute pancreatitis events, with no comparable competition in efficacy. Current guidance assumes reaching only 10% of the 1M high-risk U.S. sHTG patients, with pricing likely near $20,000 per patient annually.